Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVT3F8
|
|||
| Drug Name |
BBI-5000
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alopecia [ICD-11: ED70; ICD-9: 704.09] | Phase 2 | [1] | |
| Company |
Brickell Biotech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin D2 receptor 2 (PTGDR2) | Target Info | Antagonist | [2] |
| Reactome | Prostanoid ligand receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02590289) A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.